TBPH Q1 2025 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+6.1% YoY

Gross Profit

$4M25.6% margin

Operating Income

-$14M-93.8% margin

Net Income

-$14M-88.2% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-17.9%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$43M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$344M

Total Liabilities

$178M

Stockholders' Equity

$166M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$15M	+6.1%
Gross Profit	$4M	$6M	-28.9%
Operating Income	-$14M	-$11M	-28.8%
Net Income	-$14M	-$12M	-16.4%

Revenue Segments

YUPELRI Monotherapy

$20M57%

Collaboration revenue

$15M43%